/ACCD
ACCD Stock - Accolade, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$7.02+0.00%
+$0.00 (+0.00%) • Apr 8
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.82
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.36
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.1%upside
Target: $7.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACCD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.95 – $7.09
TARGET (TP)$7.03
STOP LOSS$6.46
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.10
52W High$9.67
52W Low$3.08
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $414.29M | $363.14M | $310.02M | $170.36M | $132.51M |
| Gross Profit | $192.06M | $164.24M | $141.00M | $76.69M | $58.82M |
| Gross Margin | 46.4% | 45.2% | 45.5% | 45.0% | 44.4% |
| Operating Income | $-114,453,000 | $135.90M | $-171,141,000 | $-46,777,000 | $-48,204,000 |
| Net Income | $-99,805,000 | $-459,650,000 | $-123,124,000 | $-50,652,000 | $-51,365,000 |
| Net Margin | -24.1% | -126.6% | -39.7% | -29.7% | -38.8% |
| EPS | $-1.33 | $-6.45 | $-1.93 | $-0.89 | $-1.05 |
Company Overview
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
44%
Hold / Neutral
9
56%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
7 Bullish9 Neutral/Bearish
Price Targets
$12
Average Target
↑ 76.9% Upside
Now
$6
Low
$12
Average
$18
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 28th 2024 | Needham | Reiterated | Buy | $8← $13 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $16 |
| January 17th 2024 | DA Davidson | Resumed | Neutral | $14← $16 |
| January 3rd 2024 | Barclays | Initiation | Equal Weight | $13 |
| May 24th 2023 | BofA Securities | Upgrade | Buy | $16.5 |
| April 12th 2023 | Stephens | Initiation | Overweight | $18 |
| March 23rd 2023 | Guggenheim | Upgrade | Buy | $16 |
| February 9th 2023 | Jefferies | Downgrade | Hold | $14 |
| February 2nd 2023 | Raymond James | Initiation | Outperform | $15 |
| September 8th 2022 | Piper Sandler | Resumed | Overweight | $12 |
| September 7th 2022 | Truist | Initiation | Buy | $15 |
| August 12th 2022 | DA Davidson | Initiation | Buy | $16 |
| May 2nd 2022 | Wells Fargo | Upgrade | Equal Weight | $6 |
| April 29th 2022 | Credit Suisse | Downgrade | Neutral | $9← $33 |
| April 29th 2022 | Morgan Stanley | Downgrade | Equal Weight | $9← $30 |
Earnings History & Surprises
ACCDBeat Rate
75%
Last 20 quarters
Avg Surprise
-13.6%
EPS vs Estimate
Beats / Misses
15/5
Last 12 quarters
Latest EPS
$-0.10
Q2 2025
EPS Surprise History
Q2 23
+18.8%
$-0.52vs$-0.64
Q4 23
+23.2%
$-0.43vs$-0.56
Q1 24
+39.1%
$-0.28vs$-0.46
Q2 24
+9.1%
$-0.10vs$-0.11
Q2 24
+27.1%
$-0.35vs$-0.48
Q4 24
+33.3%
$-0.30vs$-0.45
Q1 25
+6.3%
$-0.30vs$-0.32
Q2 25
-300.0%
$-0.10vs$0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 24, 2025 | $0.05 | $-0.10 | -300.0% | ✗ MISS |
Q1 2025 | Jan 10, 2025 | $-0.32 | $-0.30 | +6.3% | ✓ BEAT |
Q4 2024 | Oct 8, 2024 | $-0.45 | $-0.30 | +33.3% | ✓ BEAT |
Q2 2024 | Jun 27, 2024 | $-0.48 | $-0.35 | +27.1% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q1 2024 | Jan 8, 2024 | $-0.46 | $-0.28 | +39.1% | ✓ BEAT |
Q4 2023 | Oct 4, 2023 | $-0.56 | $-0.43 | +23.2% | ✓ BEAT |
Q2 2023 | Jun 29, 2023 | $-0.64 | $-0.52 | +18.8% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $-0.43 | $-0.42 | +2.3% | ✓ BEAT |
Q1 2023 | Jan 9, 2023 | $-0.61 | $-0.56 | +8.2% | ✓ BEAT |
Q4 2022 | Oct 6, 2022 | $-0.71 | $-0.66 | +7.0% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-0.73 | $-0.40 | +45.2% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $-0.23 | $-0.27 | -17.4% | ✗ MISS |
Q1 2022 | Jan 10, 2022 | $-0.48 | $-0.39 | +18.7% | ✓ BEAT |
Q4 2021 | Oct 7, 2021 | $-0.45 | $-0.43 | +4.4% | ✓ BEAT |
Q3 2021 | Jul 8, 2021 | $-0.32 | $-0.39 | -21.9% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-0.07 | $0.02 | +128.6% | ✓ BEAT |
Q1 2021 | Jan 7, 2021 | $-0.33 | $-0.26 | +21.2% | ✓ BEAT |
Q4 2020 | Oct 14, 2020 | $-0.40 | $-0.41 | -2.5% | ✗ MISS |
Q3 2020 | Aug 13, 2020 | $-0.40 | $-1.69 | -322.5% | ✗ MISS |
Frequently Asked Questions about ACCD
What is ACCD's current stock price?
Accolade, Inc. (ACCD) is currently trading at $7.02 per share. The stock has moved +0.00% today.
What is the analyst price target for ACCD?
The average analyst price target for ACCD is $7.03, based on 1 analyst.
What sector is Accolade, Inc. in?
Accolade, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is ACCD's market cap?
Accolade, Inc. has a market capitalization of $0.58 billion, making it a small-cap company.
Does ACCD pay dividends?
No, Accolade, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPEN
Apollo Endosurgery, Inc.
$10.00
Mkt Cap: $0.6B
BDSI
BioDelivery Sciences International, Inc.
$5.59
Mkt Cap: $0.6B
CTEV
Claritev Corporation
$41.02
Mkt Cap: $0.7B
EXAI
Exscientia plc
$4.84
Mkt Cap: $0.6B
MPLN
MultiPlan Corporation
$23.15
Mkt Cap: $0.4B
RGLS
Regulus Therapeutics Inc.
$8.16
Mkt Cap: $0.6B
SAGE
Sage Therapeutics, Inc.
$8.68
Mkt Cap: $0.5B
SHCR
Sharecare, Inc.
$1.43
Mkt Cap: $0.5B
SLGC
SomaLogic, Inc.
$2.10
Mkt Cap: $0.4B
Explore stocks similar to ACCD for comparison